Abbott

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Abbott 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABT

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. 

CEO
Robert B. Ford
CEORobert B. Ford
Employees
114,000
Employees114,000
Headquarters
Abbott Park, Illinois
HeadquartersAbbott Park, Illinois
Founded
1888
Founded1888
Employees
114,000
Employees114,000

ABT Key Statistics

Market cap
195.12B
Market cap195.12B
Price-Earnings ratio
30.08
Price-Earnings ratio30.08
Dividend yield
2.14%
Dividend yield2.14%
Average volume
8.92M
Average volume8.92M
High today
$112.64
High today$112.64
Low today
$111.18
Low today$111.18
Open price
$111.99
Open price$111.99
Volume
6.97M
Volume6.97M
52 Week high
$141.23
52 Week high$141.23
52 Week low
$105.27
52 Week low$105.27

Stock Snapshot

As of today, Abbott(ABT) shares are valued at $112.50. The company's market cap stands at 195.12B, with a P/E ratio of 30.08 and a dividend yield of 2.1%.

During the trading session on 2026-02-21, Abbott(ABT) shares reached a daily high of $112.64 and a low of $111.18. At a current price of $112.50, the stock is +1.2% higher than the low and still -0.1% under the high.

Trading activity shows a volume of 6.97M, compared to an average daily volume of 8.92M.

The stock's 52-week range extends from a low of $105.27 to a high of $141.23.

The stock's 52-week range extends from a low of $105.27 to a high of $141.23.

ABT News

TipRanks 13h
Abbott Laboratories Streamlines Governance With Smaller Board

Abbott Laboratories ( (ABT) ) has issued an announcement. On February 20, 2026, Abbott Laboratories’ board of directors approved an amendment to the company’s...

TipRanks 13h
Exact Sciences shareholders approve acquisition by Abbott

Exact Sciences (EXAS) announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (ABT) at the special meeting of stoc...

Nasdaq 2d
ABT April 17th Options Begin Trading

Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the April 17th expiration. One of the key inputs that goes into the p...

ABT April 17th Options Begin Trading

Analyst ratings

71%

of 31 ratings
Buy
71%
Hold
29%
Sell
0%

More ABT News

Nasdaq 2d
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.

When most of us think of winning in the stock market, we envision stocks in our portfolios gaining. And that's definitely a huge part of investment success. But...

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Simply Wall St 5d
A Look At Abbott Laboratories Valuation As Libre 3 Lawsuit Raises Product Safety Concerns

Abbott Laboratories (ABT) is under fresh legal scrutiny after a wrongful death lawsuit linked alleged defects in its FreeStyle Libre 3 glucose monitors to multi...

A Look At Abbott Laboratories Valuation As Libre 3 Lawsuit Raises Product Safety Concerns

People also own

Based on the portfolios of people who own ABT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.